Assembly Biosciences (ASMB)
Develops antiviral and liver-disease candidates through discovery and clinical development.
Something off on this page? Send us feedback.
A biotechnology company that discovers and clinically develops antiviral and liver-disease candidates. Its model depends on the Gilead collaboration and outside manufacturers, with no approved products generating sales revenue.
Develops antiviral and liver-disease candidates from discovery through clinical development. HSV helicase-primase inhibitor programs and hepatitis B virus research form its core work.
The 2014 Assembly Pharmaceuticals combination shifted the listed company from specialty pharmaceuticals to virology research, making Assembly the successor to Ventrus. Under a long-term Gilead R&D collaboration, Gilead holds program opt-in rights.
Operations are based in South San Francisco, where research and clinical development are conducted. The company depends on third-party manufacturers for investigational-product supply, does not plan to build manufacturing facilities, and has no approved products generating sales revenue.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 1, 2026 | Mizuho Securities | Target | Target: $45 | Target: $53 |
| Sep 1, 2026 | UBS | Initiate | Rating: —Target: — | Target: $52 |
| Aug 18, 2026 | H.C. Wainwright | Reiterate | Rating: —Target: — | Target: $50 |
| Jun 15, 2026 | Mizuho Securities | Target | Target: $40 | Target: $45 |
| Nov 20, 2025 | Mizuho Securities | Target | Target: $36 | Target: $40 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $320.4M · Total debt $2.4M · Total assets $330.8M · Shareholders' equity $305.6M
- Revenue
- $13.4M
- Operating income
- −$6.3M
- Net income
- −$3.9M
No dividends on record.
| Institutions | 92.23% | 18.78M shares | |
|---|---|---|---|
| 97 holders · as of Jun 30, 2026 | |||
| Insiders | 7.13% | 1.45M shares | |
| 10 holders · as of Jun 18, 2026 | |||
| Strategic holders | 6.59% | 1.34M shares | |
| 1 holder · as of Dec 8, 2025 | |||
| Adds to | 105.95% | ||
20.36M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 105.95%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Gilead Sciences, Inc.Institution | 24.44% | 4.98M | as of Jun 30, 2026 |
Farallon Capital Management LLCInstitution | 7.88% | 1.60M | as of Jun 30, 2026 |
Paradigm Biocapital Advisors LPInstitution | 7.63% | 1.55M | as of Jun 30, 2026 |
Commodore Capital LPInstitution | 6.95% | 1.42M | as of Jun 30, 2026 |
Janus Henderson Group PLCStrategic | 6.59% | 1.34M | filed Dec 8, 2025 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jun 17, 2026 | Jeanette M. Bjorkquist | officer: PFO and PAO | −29 | $23.25 |
| Mar 30, 2026 | Nicole S. White | officer: Chief Manufacturing Officer | −197 | $26.69 |
| Mar 30, 2026 | Jeanette M. Bjorkquist | officer: PFO and PAO | −328 | $26.69 |
| Aug 8, 2025 | Gilead Sciences, Inc. | 10 percent owner | +4,591,840 | $10.80 |
- GSK (ADR)
HBV functional-cure and therapeutic HSV vaccine programs.
- Arbutus Biopharma
Chronic HBV programs built around imdusiran and AB-101.
- VirBio
HBV and HDV regimen development with tobevibart and elebsiran.
- Enanta Pharmaceuticals
Oral HBV core-inhibitor program for combination regimens.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Assembly Biosciences | $25.71 | +1.07% | $504.2M | 46.3 | — | 6.7 | +38.9% |
| GSK (ADR) | $50.85 | −0.45% | $102.34B | 16.1 | 9.3 | 2.3 | +5.3% |
| Arbutus Biopharma | $5.01 | +0.10% | $987.7M | 6.4 | — | 5.4 | −90.6% |
| VirBio | $11.31 | +3.97% | $1.83B | — | — | 6.1 | +19,582.5% |
| Enanta Pharmaceuticals | $12.28 | +1.37% | $352.1M | — | — | 5.4 | −21.6% |
| Median | 11.3 | 9.3 | 5.4 | −8.2% |